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AbstrAct
Immunomodulatory therapies, targeting the immune checkpoint receptor-ligand 
complex PD-1/PD-L1 have shown promising results in early phase clinical trials 
in solid malignancies, including carcinomas of the head and neck. In this context, 
PD-L1 protein expression has been proposed as a potentially valuable predictive 
marker. In the present study, expression of PD-L1 and PD-1 was evaluated by 
immunohistochemistry in 80 patients with predominantly HPV-negative oral squamous 
cell carcinomas and associated nodal metastasis. In addition, CD274/PD-L1 gene copy 
number status was assessed by fluorescence in situ hybridization analysis. PD-L1 
expression was detected in 36/80 (45%) cases and concordance of PD-L1 expression 
in primary tumor and corresponding nodal metastasis was present in only 20/28 
(72%) cases. PD-1 expression was found in tumor-infiltrating lymphocytes (TILs) 
but not in tumor cells. CD274/PD-L1 gene amplification was detected in 19% of 
cases, with high level PD-L1 amplification present in 12/80 (15%), and low level 
amplification in 3/80 (4%). Interestingly, CD274/PD-L1 gene amplification was 
associated with positive PD-L1 immunostaining in only 73% of cases. PD-L1 copy 
number status was concordant in primary tumor and associated metastases. Clinically, 
PD-L1 tumor immunopositivity was associated with a higher risk for nodal metastasis 
at diagnosis, overall tumor related death und recurrence. Based on our findings we 
propose to include PD-L1 copy number status in addition to protein status in screening 
programs for future clinical trials with immunotherapeutic strategies targeting the 
PD-1/PD-L1 axis.
IntroductIon
Squamous cell carcinomas comprise over 95% of 
malignant tumors in the head and neck region, including 
the oral cavity. The disease is associated with a poor 
prognosis, with an overall 5-year survival rate of 60%. 
Two-thirds of the tumors present with locally advanced 
or metastatic disease (stages III and IV). Historically, oral 
cavity squamous cell carcinoma (OCSCC) was viewed 
as a tobacco- and alcohol-related cancer, but infection 
with human papillomaviruses (HPVs) has emerged as 
an important risk factor for OCSCCs (reviewed in [1]) 
Treatment recommendations according to the National 
Comprehensive Cancer Network include surgery for 
patients with early-stage tumors and surgery or definitive 
concurrent chemoradiotherapy for those with advanced-
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staged tumors [2].
Tumor immunotherapy targeting the immune 
regulatory molecules programmed death 1 (PD-1) and 
its ligand programmed death-ligand 1 (PD-L1) have 
shown antitumor effects in a subset of patients with solid 
tumors and have become an interesting prospect for the 
treatment of head and neck squamous cell carcinoma 
(HNSCC). HNSCC is an immunosuppressive disease, 
with tumor cells evading the host immune system through 
a number of mechanisms, including alteration of their own 
immunogenicity and production of immunosuppressive 
mediators (reviewed in [3]). The PD-1/PD-L1 pathway 
is important for tumor immune escape and promotion 
of the tumor microenvironment. PD-L1 is a 290aa type 
I transmembrane surface glycoprotein constitutively 
expressed on T-cells, B-cells, myeloid dendritic cells and 
tissue macrophages. PD-L1 is encoded by the CD274/
PD-L1 gene, located on chromosome 9p24.1, in close 
proximity to PDCD1LG2 (programmed cell death ligand 
2). PD-L1 can be upregulated in tumor cells and in a 
number of different tissue types in response to INF-γ and 
other inflammatory mediators [4]. Its receptor PD-1 is an 
immune checkpoint protein, expressed on the surface of 
several immune cells, particularly cytotoxic T-cells [4-6]. 
Tumor immune escape can occur through several potential 
mechanisms, mediated by high tumor expression of PD-
L1 and/or tumor immune infiltration by PD-1-positive 
T-lymphocytes: (1) Binding of PD-L1 by PD-1 on T-cells 
can lead to functional anergy or apoptosis of T-cells. (2) 
In regulatory T-cells (Tregs), ligation of PD-1 by PD-L1 
can potentially induce immunologic tolerance. (3) Reverse 
signaling from PD-L1 may prevent tumor cells from 
apoptosis and (4) PD-L1 interaction with the CD80 ligand 
can promote inhibition of immune response [7-13]. 
Aberrant PD-L1 expression has been demonstrated 
in many solid cancers [14], including melanoma [15, 
16], lung cancer [17, 18] and colon cancer [19, 20]. 
Moreover, selective 9p24.1 gene amplification has 
recently been identified as an important mechanism 
for increased PD-L1 protein expression in nodular 
sclerosing Hodgkins lymphoma and primary mediastinal 
large B-cell lymphoma [21]. Subsequently, 9p24.1 gene 
amplification has been detected in a subgroup of gastric 
carcinoma, colon carcinomas, triple-negative breast 
cancers and glioblastomas [22, 23]. In a meta-analysis of 
25 studies, Wu et al showed that overexpression of PD-
L1 is associated with worse 3-year overall survival (OS) 
in esophageal, hepatocellular and urothelial carcinoma as 
well as gastric cancer whereas this association was not 
found in carcinomas of the lung and melanoma [14].
In HNSCC, limited data suggest that PD-L1 is 
expressed in tumor cells in 50-70% of the cases and 
that PD-1-positive tumor infiltrating lymphocytes (TIL) 
may be more common in cancers that are HPV positive 
than HPV-negative [24-30]. PD-L1 expression is found 
in various HNSCC tumor cell lines and upregulation 
was demonstrated in response to the proinflammatory 
cytokines INF-γ, TNF-α and IL-1β. Interestingly, in a 
preclinical HNSCC model system, PD-1 mediated signals 
on T-cells can inhibit antitumor immune response [27, 31].
To further explore the PD-1/PD-L1 axis in HNSCC, 
we evaluated and compared frequencies of PD-1 and PD-
L1 immunohistochemical expression in a clinically well 
characterized cohort of OCSCCs of 80 primary tumors 
and 28 associated nodal metastasis and determined its 
prognostic impact. In addition we analyzed the PD-L1 
gene locus on 9p24.1 by fluorescence in situ hybridization 
(FISH) and identify PD-L1 amplification as an important 
mechanism of PD-L1 upregulation in OCSCC.
results
expression of Pd-l1 and Pd-1
PD-L1 expression was evaluated in tumor cells 
of primary oral cavity squamous cell carcinoma and 
associated nodal metastasis by immunohistochemistry. 
PD-L1 expression in at least 5% of tumor cells was found 
in 36/80 (45%) of OCSCCs. Mean percentage of positive 
tumor cells (any strength of expression) was 60% (range: 
15%-90%). Strong, membranous staining (3+) was found 
in 13/36 (36%) cases, intermediate staining (2+) in 13/36 
(36%) cases, whereas 10/36 (28%) cases demonstrated 
weak staining (1+) (Figure 1a-1c). In 28 of the 80 
analyzed cases, primary tumors and corresponding nodal 
metastases were available for assessment. Evaluation of 
the immunohistochemical PD-L1 staining results in these 
28 cases was performed both on tissue cores as well as 
whole tissue slides to exclude confounding effects due 
to possible tissue heterogeneity. Among 13 primary 
tumors positive for PD-L1 expression, 11/13 (85%) of 
corresponding nodal metastases showed concomitant 
positive expression of PD-L1, whereas 2/13 (15%) cases 
displayed loss of staining in the metastasis. A discrepancy 
between staining results in tissue cores and whole slides 
was only seen in one case, which showed positive PD-L1 
staining in the whole tissue section and negative staining 
in the tissue cores. In 15 primary tumors negative for PD-
L1 expression, 9/15 (60%) of matching nodal metastases 
were PD-L1 negative, whereas 6/15 (40%) cases were PD-
L1 positive. Altogether, in 20/28 (72%) cases, concordant 
PD-L1 expression was found in matched primary 
tumors and nodal metastases, and in 8/28 (28%) cases a 
discordance of PD-L1 expression was present in primary 
tumor specimen and corresponding nodal metastases 
(Figure 2). 
We next evaluated PD-1 expression in 
both neoplastic as well as inflammatory cells by 
immunohistochemistry. 79 cases were available for IHC. 
PD-1 was not expressed in tumor cells whereas tumor-
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Figure 1: squamous cell carcinoma of the head and neck, showing membraneous Pd-l1 expression in tumor cells with 
a. strong staining (3+), b. intermediate staining (2+) and c. weak staining (1+) intensity. Fibroblasts within tumor stroma are negative. d) 
PD-1 staining in squamous cell carcinoma with intermingled tumor-infiltrating lymphocytes (TILs). PD-1 staining is only seen in TILs, 
while carcinoma cells are negative. (a.-c. PD-L1 immunohistochemistry, d. PD-1 immunohistochemistry).
Figure 2: concordance and discordance of Pd-l1 expression in primary tumor and matched lymph node metastases.
Oncotarget12027www.impactjournals.com/oncotarget
infiltrating lymphocytes (TILs) showed PD-1 staining. 
41/79 (52%) cases contained PD-1 positive TILs. Mean 
percentage of PD-1 positive TILs was 6% (range 3%-
20%). 25/36 (69%) PD-L1 positive carcinomas and 
16/43 (37%) of PD-L1 negative carcinomas contained 
PD-1 positive TILs (Figure 1d). There was no significant 
correlation of PD-L1 and PD-1 expression.
evaluation of CD274/PD-L1 copy number status 
by fluorescence in situ hybridization
Given the broad range of PD-L1 
immunohistochemical expression in OCSCC, which 
could not be easily explained by autocrine or paracrine 
upregulation, we further explored the copy number status 
of the CD274/PD-L1 gene locus by FISH. PD-L1 FISH 
analysis was performed in all 80 primary tumors and in 
16 corresponding lymph node metastases. 15/80 (19%) 
primary tumors fulfilled the criteria for amplification: in 
12/80 cases (15%), high level amplification of the PD-L1 
gene locus, as defined by PD-L1/CEP9 ratio ≥ 4.0 was 
seen (Figure 3a,3b) and 3/80 (4%) cases showed low-
level PDL-1 amplification as defined by PD-L1/CEP9 
ratio ≥ 2.0 and ≤ 4.0 (Figure 3c). Gene copy number gain 
was restricted to tumor cells and was not present in the 
inflammatory cell component. A polysomy defined as 
average PD-L1 copy number > 3 signals/cell was seen in 
16/80 (20%) cases (Figure 3d). 49/80 (61%) cases were 
disomic for the PD-L1 gene locus at 9.24.1 (Figure 3e). 
The PD-L1 copy number status was concordant in the 
primary tumor and corresponding lymph node metastases.
table 1: clinicopathological data in relation to Pd-l1 immunohistochemical expression.
clinicopathologic Parameters Pd-l1 positive Pd-l1 negative 
n (%) 36 (45%) 44 (55%)
Median age (years)
Age range (years) 5738-86
60
44-84
Gender 
Male
Female
23 (64%)
13 (36%)
31 (70%)
13 (30%)
Differentiation 
G1
G2
G3
1 (3%)
29 (80%)
6 (17%)
3 (7%)
27 (61%)
14 (32%)
Tumor Size 
T1
T2
T3
T4a/b
4 (11%)
15 (42%)
5 (14%)
12 (33%)
8 (18%)
17 (39%)
9 (20%)
10 (23%)
Lymph node metastasis 
Positive
Negative
26 (72%)
10 (28%)
19 (43%)
25 (57%)
HPV (Type 16) 
Positive
Negative
1 (3%)
35 (97%)
4 (9%) 
40 (91%)
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Figure 3: Fluorescence in situ-hybridization (FIsH) for PD-L1. PD-L1 gene is labelled in green, centromer 9 in red. FISH 
analysis showing a., b. high level amplification, with PD-L1/CEP9 ratio ≥ 4, indicated by clusters of green fluorochrome labeling PD-
L1 c. low level amplification, PD-L1/CEP9 ratio ≥ 2.0 - < 4; d. Polysomy of PD-L1 gene locus; e. PD-L1 disomy. (a.-d. SPEC CD274, 
PDCD1LG2/CEN9 Dual Color Probe).
Figure 4: overall tumor-related survival and recurrence-free survival in patients with scc of the oral cavity with 
respect to Pd-l1 immunohistochemical status. Overall tumor-related survival a. and recurrence-free survival b. is worse in SCC 
patients with tumoral PD-L1 immunopositivity (p = 0.01 and 0.05, respectively).
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correlation between PD-L1 gene amplification 
and PD-L1 copy number gain with Pd-l1 protein 
expression
Results for both PD-L1 immunohistochemistry and 
CD274/PD-L1 FISH were available for all 80 cases (Table 
2 and Supplementary Table 1). Tumors with CD274/
PD-L1 gene amplification displayed PD-L1 positivity 
by immunohistochemistry in only 11/15 (73%) cases. 
In contrast, 25/65 (38%) cases without CD274/PD-L1 
amplification were PD-L1 immunopositive. Cases with 
CD274/PD-L1 amplification were PD-L1 immunopositive 
in a significantly higher frequency than cases without 
amplification (p = 0.01). 7/13 carcinomas with strong, 
membranous PD-L1 immunostaining (score 3+) showed 
high or low level CD274/PD-L1 amplification, 3/13 
showed a polysomy and 3 cases displayed a normal copy 
number status. Interestingly, two of the highly amplified 
carcinomas and two of the tumors with low-level CD274/
PD-L1 amplification were PD-L1 immunonegative 
(score 0). To confirm the findings and to exclude false 
negative staining due to tumor heterogeneity in these 4 
cases, FISH analysis and immunohistochemistry were 
repeated on whole tissue sections, giving identical results. 
Altogether, 40/80 (50%) cases were negative for both PD-
L1 immunohistochemistry and PD-L1 FISH.
correlation of Pd-1, Pd-l1 expression and 
CD274/PD-L1 amplification in tumor tissue with 
clinicopathologic features
All features of clinicopathological data in relation to 
PD-L1 immunohistochemical expression are summarized 
in Table 1. In 5 cases, HPV DNA was detected, indicating 
HPV associated carcinogenesis, with one of these cases 
showing CD274/PD-L1 high level amplification and PD-
L1 immunopositivity. The remaining four cases did not 
express PD-L1. Patients with PD-L1 immunopositive 
tumors had a significantly higher risk for lymph node 
metastasis at diagnosis (p-value = 0.009), whereas PD-
L1 immunohistochemical expression was not relevantly 
correlated with age, gender, grading, tumor size or HPV-
positivity. In contrast, both CD274/PD-L1 copy number 
status and PD-1 immunohistochemical expression were 
found to be not relevantly correlated with the presence of 
nodal metastases and were also not relevantly correlated 
with age, gender, grading, tumor size, or HPV-positivity.
correlation of Pd-l1 expression with clinical data
In the SCC patient cohort with PD-L1 
immunopositive tumors, the risk of tumor related death 
was significantly increased (p = 0.01) (Figure 4a) which 
was also the case for the risk of recurrence (p = 0.05) 
(Figure 4b). In contrast, PD-1 expression, CD274/PD-
L1 copy number, pT category, presence of lymph node 
metastases or tumor grading were not relevantly associated 
with these risks (data not shown). 
dIscussIon
Malignant tumors can escape the host´s immune 
system by a process termed “immunoediting”, turning the 
immune microenvironment into an immunosuppressive 
state. An important pathway in the immune anti-tumor 
response is the PD-1/PD-L1 axis [10, 32, 33]. PD-L1 
expression in tumor cells is thought to be predictive for 
tumor response to immunomodulatory therapies targeting 
the PD-1/PD-L1 pathway [34]. Data on PD-1 and PD-L1 
expression in HNSCC concerning prevalence, prognostic 
impact and variation of expression in disease course is 
limited.
In the present study, we provide novel molecular 
genetic evidence that the CD274/PD-L1 gene is amplified 
in OCSCC and that gene amplification is accompanied 
by immunohistochemical PD-L1 protein overexpression 
in only a subset of amplified cases. We also demonstrate 
that the PD-L1 protein expression status in primary tumors 
and corresponding nodal metastasis is discordant in a 
significant number of cases investigated.
Using immunohistochemistry and a cut-off value 
for positivity defined as at least 5% tumor cells displaying 
membranous PD-L1 staining, we found PD-L1 expression 
in 36/80 (45%) of OCSCC, a range similar to published 
data. To date, only few studies have evaluated PD-
L1 expression in OCSCC [27] [31] [24] [25] [28] with 
positivity rates ranging between 46%-87%. These variable 
positivity rates are likely due to several factors: (1) Use 
of different cut-off values for definition of positivity; for 
example, a study by Ukpo et al used a cut-off value of 5%, 
table 2: CD274/PD-L1 FIsH and Pd-l1 immunohistochemistry.
CD274/PD-L1 FIsH cases Pd-l1 IHc
n = 80 score 3+
score 
2+
score 
1+
score 
0
High Level Amplification 12 (15%) 7/12 1/12 2/12 2/12
Low Level Amplification 3 (4%) 1/3 0/3 0/3 2/3
Polysomy 16 (20%) 3/16 3/16 3/16 7/16
Disomy 49 (61%) 3/49 8/49 5/49 33/49
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whereas Badoual et al and Strome et al defined positivity 
as any staining > 0% [27] [24] [28]; (2) cytoplasmic 
staining, in addition to membranous staining was counted 
as positive by some authors; (3) use of different antibodies 
clones for immunohistochemistry [27] [31] [24] [25] [28] 
and (4) inclusion of a high percentage of HPV-positive 
cases in one of the studies [28].
Up to date, there is limited data concerning 
changes of PD-L1 expression in tumors during metastatic 
progression and none of the studies up to date have 
evaluated SCCs of the head and neck. Results of our own 
study show that in only 72% of cases, the PD-L1-status 
was retained in nodal metastatic lesions. In two studies 
comparing matched tumor samples with corresponding 
metastatic lymph nodes involving patients with RCC 
and triple-negative breast cancer, respectively, the 
concordance rates were considerably higher [33, 35]. 
Tissue heterogeneity of PD-L1 protein expression or 
change of PD-L1 expression during metastatic disease 
progression might contribute to low concordance rates, but 
further functional follow up studies are needed to clarify 
this issue. 
Tolerance of PD-L1 positive tumors by the immune 
system is mediated by interaction of PD-L1 on tumor 
cells with its receptor PD-1, preferentially expressed on 
Tregs and other immune cells. Upon activation of PD-1/
PD-L1, the anti-tumor response of the immune system 
is attenuated as T-cell functions are suppressed by the 
mechanisms named above. In HNSCC, co-receptor 
signals on T-cells mediated by PD-1 can inhibit antitumor 
response in a pre-clinical model [8, 27, 33, 36, 37]. In 
our study cohort, all primary tumors were PD-1 negative, 
whereas PD-1 was expressed in TILs in 24/36 (67%) 
PD-L1 positive carcinomas and 16/43 (37%) of PD-L1 
negative. Absolute numbers of positive TILs were low in 
comparison to previous studies [9], [26] and may reflect 
differences between the pathogenesis of OCSCC and 
other anatomical regions of the head and neck like the 
oropharynx, where HPV induced carcinogenesis is more 
prevalent. 
In our OCSCC patient cohort, PD-L1 positive 
carcinomas had a significantly higher risk for nodal 
metastasis at the time of diagnosis (p-value 0.01). 
Moreover, the risk of disease-and overall tumor-related 
death was significantly higher in PD-L1 positive OCSCC. 
In comparison, results of previous studies have been 
contradicting in this regard, probably reflecting differences 
in methodologies used to assess PD-L1 status and 
differences in patient characteristics, including percentage 
of HPV-related SCC tumor subgroups [25] [28]. It is well 
known that human papillomavirus (HPV)-associated 
HNSCCs tend to have improved clinical outcomes when 
compared to tobacco-related head and neck cancers. In 
contrast to oropharyngeal cancer, where HPV has been 
recognized as an important causative factor for tumor 
development, its influence on OCSCC pathogenesis is less 
clear and prevalence rates are much lower. 
Expression of PD-L1 in tumors cells is mediated 
by different mechanisms. It can be induced by autocrine 
or paracrine factors within the tumor microenvironment, 
especially INF-γ or HIF1α. In this case, PD-L1 expression 
is dynamic, with variable, time-dependent expression. 
On the other hand, expression can be driven by gene 
amplification events involving the 9p24.1 locus. The 
9p24.1 chromosomal locus contains the CD274/PD-
L1, PD-L2 and JAK2 genes [21, 23]. Selective 9p24.1 
amplification has been recently recognized as an 
important mechanism for increased PD-L1 expression 
in nodular sclerosing Hodgkins lymphoma and primary 
mediastinal large B-cell lymphoma [21] and has also been 
demonstrated in gastric carcinoma, colon carcinomas, 
triple-negative breast cancers and glioblastomas [22, 
23]. Other signaling pathways, which have been linked 
to oncogene-induced PD-L1 expression are, amongst 
others, loss of PTEN and dysregulation of the JAK/STAT 
pathway, the latter probably providing an additional 
“enhancer loop” for PD-L1 overexpression when JAK2 is 
amplified [16, 36, 38-40]. 
Using FISH analysis, we found amplification of 
9p24.1, including the CD274/PD-L1 gene locus, in 19% of 
OCSCC cases. The amplification driven PD-L1 expression 
in a subgroup of OCSCC may identify a new subgroup 
of HNSCC with a disease-specific genetic alteration. 
Further studies are needed to evaluate the impact of PD-L1 
amplification on pathogenesis and disease progression and 
on prognosis of this newly identified subgroup of HNSCC. 
Blocking the PD-1/PD-L1 axis is a promising 
treatment option in multiple tumor types. Up to date, 
several clinical studies have been conducted, including 
especially patients with melanoma and non-small cell 
lung cancer (NSCLC), but also HNSCC (reviewed in [3]). 
These studies have demonstrated better response rates in 
patients with high PD-L1 expression. In addition, immune 
checkpoint blockage has shown remarkable response rates 
in lymphomas, especially Hodgkins lymphoma, with PD-
L1 amplification [41]. Response to anti-PD-1 treatment 
was also found, in a significantly lower percentage, in 
PD-L1 negative cases [8, 33, 42-45]. Considering the fact 
that the interaction of PD-L1 on tumor cells with PD-1 
on TILs leads to escape of cancer cells from the immune 
system, it is not surprising, that upregulation of PD-1 by 
recombinant cytokines, stimulatory antibodies or transfer 
of activated adoptive T-cells increases the effect of PD-1/
PD-L1 pathway blockage [27, 46, 47]. The identification 
of CD274/PD-L1 gene copy number gain as a potential 
mechanism for PD-L1 overexpression in the present 
study may provide a rationale for treatment of HNSCC 
patients, especially in a subgroup of OCSCC with PD-
L1 amplification. Future studies have to investigate 
whether PD-L1 copy number status, which is stable in the 
primary tumor and corresponding lymph node metastasis, 
might be a better predictive marker for tumor response 
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to blockage of PD-1/PD-L1 pathway [34] than PD-L1 
immunohistochemical status. In any case, the correlation 
between CD274/PD-L1 gene amplification and the PD-
L1 immunohistochemical status is surprisingly poor, with 
4 amplified cases being PD-L1 immunonegative. The 
reason for this discrepancy is currently not clear, but may 
involve technical problems with the antibody clone used 
or posttranscriptional or posttranslational modifications.
In summary, we show that PD-L1 is expressed in 
45% of OCSCC, when a 5% cut-off of positive cells is 
applied. PD-L1 positive cases have a significantly higher 
risk for nodal metastasis at diagnosis. PD-L1 expression 
is associated with higher risk for overall tumor-related 
death and recurrence. Although PD-L1 expression 
status in corresponding nodal metastasis is equivalent to 
expression in primary tumors in the majority of cases, 
a considerable number of cases (32%) were discordant. 
CD274/PD-L1 amplification is a novel finding in OCSCC 
and is a frequent event, often (but not always) associated 
with high PD-L1 expression levels and stable during 
metastatic progression. Based on these data, we propose to 
include CD274/PD-L1 amplification analyses into studies 
recruiting patients for immune checkpoint protocols.
MAterIAls And MetHods
Patient cohort
The retrospective cohort consisted of 80 patients, 
who underwent surgical resection of squamous cell 
carcinoma of the oral cavity between 2008 and 2010 at 
the Klinikum rechts der Isar of the Technical University of 
Munich, Germany. H&E stained sections were reviewed 
by three pathologists (MS, ED, KS). Grading and staging 
was undertaken according to the current World Health 
Organization Classification of Tumors of Head and Neck 
(2004) and the AJCC tumor, node, metastasis (TNM) 
classification (7th edition). Complete clinicopathologic 
data including age, gender, localization of primary 
tumor, local, nodal and distant recurrences and overall 
and disease-free survival were available for all patients 
(Supplementary Table 1). All patients underwent primary 
resection of tumors with curative intent following a 
standardized surgical procedure [48]. Patients did not have 
distant metastasis at diagnosis. Patients with lymph node 
metastasis at diagnosis received adjuvant radiotherapy. 
Mean follow-up was 31 months (range 2 - 63 months). 
Approval for the study was obtained from the Ethics 
Review Committee of the Technical University of Munich.
tissue microarray construction
Formalin-fixed paraffin-embedded tumor samples 
were assembled into a tissue microarray (TMA) using a 
Tissue Microarrayer (Beecher Instruments, Sun Praierie, 
USA) with a core size of 0,6 mm. A minimum of 2 and 
(where feasible) up to 4 tumor cores from tumor invasion 
front and tumor center were taken from the primary 
tumors in areas previously marked by two pathologists 
(MS, ED). Corresponding regional nodal metastasis from 
28 patients were also included in the TMA, selecting 1 
or (where feasible) 2 different areas from the metastatic 
deposits, depending on size of metastasis.
Immunohistochemistry
IHC was performed on 2 µm sections from 
each TMA using a PD-L1 primary antibody (Cell 
Signaling, clone E1L3N) at a dilution of 1:100 and a 
PD-1 primary antibody (Cell Marque, clone 11RQ-
22) at a dilution of 1:50. Stainings were run on an 
automated immunostainer with an iVIEW DAB detection 
kit (Ventana Medical Systems, Roche, Mannheim, 
Germany). Immunohistochemical expression of PD-L1 
in tumor cells was assessed by counting the percentage 
of positive tumor cells and quantifying staining intensity 
in a 4-tiered grading system including “no staining” 
(0), “weak staining” (1+), “intermediate staining” (2+), 
“strong staining” (3+). PD-L1 positivity was arbitrarily 
defined as at least 5% tumor cells displaying membranous 
PD-L1 staining of any intensity. The cut-off value of 
5% was chosen, because many clinical trials involving 
immunomodulatory therapeutics have chosen this value. 
Immunohistochemical expression of PD-1 in TILs was 
assessed by counting the percentage of PD-1 positive 
TILs. PD-1 positivity was counted as at least 1% positive 
TILs.
PD-L1 fluorescence in situ hybridization
Dual-color FISH analysis was performed on 2µm 
sections from formalin-fixed paraffin-embedded tissue. 
Sections were deparaffinized, dehydrated in 100% 
ethanol and air-dried. For in situ hybridization, the SPEC 
CD274, PDCD1LG2/CEN9 Dual Color Probe containing 
a mixture of fluorochrome direct labelled SPEC CD274, 
PDCD1LG2 probe specific for the CDC274/PD-L1 and 
PDCD1LG2/PD-L2 genes located at 9p24.1 and an 
orange fluorochrome labeled CEN 9 probe specific for 
the classical satellite III region of chromosome 9 (D9Z3) 
at 9q12 (Zytovision, Bremerhaven, Germany) was used 
according to the manufacturer´s instructions. At least 20 
nuclei per sample were counted. PD-L1 amplification 
was defined as PD-L1/CEP9 ratio ≥ 2.0, with high level 
amplification defined as ≥ 4.0 and low level amplification 
defined as ≥ 2.0 and ≤ 4.0. Polysomy 9 was defined as 
average PD-L1 copy number > 3 signals/cell.
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HPV analysis
DNA was isolated from formalin-fixed, paraffin-
embedded tissue of primary tumor samples using the 
QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, 
Germany) in combination with the QiaCube (Qiagen, 
Hilden, Germany) according to the supplier’s instructions. 
HPV analysis and determination of HPV subtypes was 
performed with the HPV LCD 3.5 Array - Kit (Chipron 
GmbH, Berlin, Germany) according to the manufacturer’s 
recommendations.
statistics
Descriptive and exploratory statistical analyses were 
performed using SPSS 21 (SPSS Inc, Chicago, IL, USA) 
and R 3.2.0 (R Foundation for Statistical Computing, 
Vienna, Austria). The distribution of qualitative data 
was compared between groups using χ²-test or Fisher’s 
exact test, depending on the cell counts of corresponding 
contingency tables. Likewise, quantitative data was 
compared between groups using the non-parametric 
Mann-Whitney U test. Cumulative incidence functions 
were estimated for censored outcomes to account for 
competing risks such as death. All statistical tests were 
performed on exploratory two-sided 5% significance 
levels.
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